Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic NSCLC ...
The decision by the Canadian regulator is supported by the findings from the Phase III DESTINY-Breast06 study.
ESMO 2025 showcased the breadth and urgency of breast cancer research, which remains one of the most diagnosed malignancies ...
Health Canada has granted a Notice of Compliance (NOC) for Enhertu® (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...
Mayo Clinic researchers have discovered a key reason why certain breast cancers might not respond to an important new class of therapeutics called ...
We project that in the next six weeks, the probability of a U.S. recession getting started in the next twelve months will be ...
TipRanks on MSN
Daiichi Sankyo’s Promising Study on Ifinatamab Deruxtecan: A Potential Game-Changer in Oncology
Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Daiichi Sankyo Company (DSKYF) is currently conducting a ...
Patients with advanced triple negative breast cancer ineligible for immunotherapy may overcome their typically poor prognosis ...
Actinium Pharmaceuticals (ATNM) announced the presentation of the first ever preclinical data of ATNM-400 in non-small cell lung cancer, or NSCLC.
Researchers present an overview of treatment and management strategies for patients with HR+/HER2+ breast cancer, including common adverse effects.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback